EyePoint Pharmaceuticals presented 12 month efficacy and safety data supporting its YUTIQ three-year micro-insert for noninfectious posterior segment uveitis at the 36th Annual Scientific Meeting of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results